Humabiologics, Inc. Sustainability Profile
Humabiologics, Inc., headquartered in the United States, is a pioneering entity in the biopharmaceutical industry, specialising in the development and distribution of innovative human-derived biological products. Founded in 2015, the company has rapidly established itself as a leader in regenerative medicine, focusing on advanced cellular therapies and tissue engineering. With a commitment to quality and scientific excellence, Humabiologics offers unique products such as human amniotic membrane and umbilical cord tissue, which are utilised in various medical applications, including wound healing and orthopaedic procedures. The company’s dedication to research and development has led to significant advancements in the field, positioning it as a trusted partner for healthcare providers seeking cutting-edge solutions. Humabiologics continues to expand its operational reach, contributing to the evolving landscape of regenerative medicine.
DitchCarbon Score
How does Humabiologics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Humabiologics, Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Humabiologics, Inc.'s reported carbon emissions
Humabiologics, Inc., headquartered in the US, currently does not report any carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any specific reduction targets or initiatives related to climate commitments. As of now, there are no climate pledges or commitments to industry-standard frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). Without emissions data or reduction initiatives, it is unclear how Humabiologics, Inc. is addressing its carbon footprint or contributing to climate action within its industry. The absence of reported emissions and commitments suggests that the company may still be in the early stages of developing its climate strategy.
How Carbon Intensive is Humabiologics, Inc.'s Industry?
How Carbon Intensive is Humabiologics, Inc.'s Location?
Humabiologics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Humabiologics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
